<table>
<thead>
<tr>
<th>Session (15:00-16:00)</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S1</strong></td>
<td>Evidence in Context</td>
<td>GBR101</td>
</tr>
<tr>
<td>IMPACT OF NEW POLICY CHANGES ON NEED FOR PHARMACOECONOMIC EVIDENCE FOR REIMBURSEMENT AND MARKET ACCESS</td>
<td>Saurabh (Rob) AGGARWAL, Novel Health Strategies, United States of America One small step for an individual, one giant leap for their family: Considerations required for assessing the cost effectiveness of genetic tests</td>
<td>Skye NEWTON, Adelaide Health Technology Assessment, School of Population Health, University of Adelaide, Australia Regional assessment of therapeutic approaches for haemophilia A and B: How to choose? Rossella Di BIDINO, HTA Unit, “A.Gemelli” Teaching Hospital, Italy Getting to first base: issues with selecting the comparator David GRAINGER, Eli Lilly and Company, United States of America</td>
</tr>
<tr>
<td><strong>S2</strong></td>
<td>Identification and Management of New Technologies</td>
<td>GBR102</td>
</tr>
<tr>
<td>HORIZON SCANNING FOR EMERGING HEALTH TECHNOLOGIES ACROSS DISEASE AREAS: LESSONS LEARNT FROM LUNG CANCER.</td>
<td>Sue SIMPSON, University of Birmingham, United Kingdom Identifying clusters of new health technologies using routine information from early awareness and alert systems Derek WARD, University of Birmingham, United Kingdom A comparative study between medical specialties of technologies identified through the early awareness and alert system - SINTESES-new technologies and EUROSCAN database Setefilla LUENGO-MATOS, Agencia de Evaluación de Tecnologías Sanitarias (AETS-ISCIII), Spain Getting ahead of the curve at CADTH: innovative approaches for topic identification, prioritization and completion of projects in time for decision-making Terri O’GRADY, Canadian Agency for Drugs and Technologies in Health, Canada</td>
<td></td>
</tr>
<tr>
<td><strong>S3</strong></td>
<td>Evidence for Quality Improvement</td>
<td>GBR103</td>
</tr>
<tr>
<td>CHANGE IN PHYSICIAN BLOOD PRODUCT PERSCRIBING PATTERNS THROUGH LEAN AND SIX SIGMA PROCESS CHANGE</td>
<td>Kerry GUNN, Auckland City Hospital, New Zealand Usage of scientific and empirical evidence to support the creation of a quality model for content-based image retrieval systems Juliana P. SOUZA, Interunites Postgraduate Program in Bioengineering (EESC/FMRP/IQSC - USP), Brazil When good HTA goes bad – a lesson from the real world Stephen MUNN, Auckland District Health Board, New Zealand The effect of unpaid caregiving on labour force participation, wages and hours of work: evidence from the People’s Republic of China Huamin CHAI, Nankai University, China People’s Rep. of</td>
<td></td>
</tr>
<tr>
<td><strong>S4</strong></td>
<td>Telemedicine HTA</td>
<td>GBR104</td>
</tr>
</tbody>
</table>
### HTAi Seoul 2013 Oral sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>(15:00-16:00)</td>
<td><strong>EFFECT OF A HOME TELEMONITORING INTERVENTION IN HOSPITAL ADMISSIONS AT 2-YEAR FOLLOW-UP (THE TELBIL STUDY)</strong></td>
<td>José ASUA, Basque Office for Health Technology Assessment (Osteba), Spain</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>REMOTE MONITORING STRATEGIES AFTER RECENT HOSPITAL DISCHARGE IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</strong></td>
<td>Abdullah PANDOR, University of Sheffield, United Kingdom</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TELEMONITORING AFTER DISCHARGE FROM HOSPITAL WITH HEART FAILURE - COST-EFFECTIVENESS MODELLING OF ALTERNATIVE SERVICE DESIGNS</strong></td>
<td>Praveen THOKALA, University of Sheffield, United Kingdom</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>THE STATUS OF TELEREHABILITATION IN NEUROLOGICAL APPLICATIONS</strong></td>
<td>David HAILEY, University of Wollongong, Australia</td>
<td>Australia</td>
<td></td>
</tr>
<tr>
<td>S5 (15:00-16:00)</td>
<td><strong>COLLABORATIVE NETWORKING: HOW IT AIDS TO DECISION MAKING. THE ARGENTINIAN EXPERIENCE: RedARETS</strong></td>
<td>Veronica SANGUINE, National Ministry of Health- UCEETS- (Unidad Coordinadora en Evaluacion y Ejecucion de Tecnologias Sanitarias), Argentina</td>
<td>Argentina</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NO MORE DUPLICATION. IS THE PLANNED AND ONGOING PROJECT DATABASE A USEFUL TOOL TO INCREASE EFFICIENCY IN THE PROCESS OF ASSESSING NEW HEALTH TECHNOLOGIES IN THE EUROPEAN UNION?</strong></td>
<td>Marianne SANDVEI, University of Southern Denmark, CAST, Denmark</td>
<td>Denmark</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>EVALUATING THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUnetHTA): BRIDGING ART AND SCIENCE</strong></td>
<td>Eleanor GUEGAN, NIHR Evaluation, Trials and Studies Coordinating Centre, United Kingdom</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>BRIDGING THE GAP: COLLABORATION BEYOND OUR BOUNDARIES</strong></td>
<td>Linda MUNDY, Clinical Access and Redesign Unit, Health Service and Clinical Innovation Division, Department of Health, Discipline Public Health, University of Adelaide, Australia</td>
<td>Australia</td>
<td></td>
</tr>
<tr>
<td>S6 (15:00-16:00)</td>
<td><strong>USE OF META-REGRESSION TO DEAL WITH HETEROGENEITY WHEN PERFORMING AN INDIRECT TREATMENT COMPARISON (ITC)</strong></td>
<td>James HARRISON, Bristol-Myers Squibb, Australia</td>
<td>Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PUBLICATION OF METHODOLOGICAL GUIDELINES: THE DEVELOPMENT OF SYSTEMATIC REVIEWS (SR) AND META-ANALYSES OF RANDOMIZED CLINICAL TRIALS BY THE DEPARTMENT OF SCIENCE AND TECHNOLOGY OF THE BRAZILIAN MINISTRY OF HEALTH (DECIT/MoH)</strong></td>
<td>Christine KOURY, HTA UNIT/DEPARTMENT OF SCIENCE AND TECHNOLOGY/ BRAZILIAN MINISTRY OF HEALTH, Brazil</td>
<td>Brazil</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>GUIDELINES TO ADAPT GUIDELINES IN LATIN AMERICAN COUNTRIES</strong></td>
<td>Alicia ALEMAN, Health Technology Assessment Division of Ministry of Health of Uruguay, Uruguay</td>
<td>Uruguay</td>
<td></td>
</tr>
<tr>
<td>S7 (15:00-16:00)</td>
<td><strong>EVIDENCE AND HEALTH POLICY APPROACH TO DIFFUSION OF PET IN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Speakers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S8</td>
<td>Effectiveness Assessments</td>
<td><em>EFFECTIVENESS OF EDUCATION INTERVENTIONS FOR MANAGEMENT OF CANCER PAIN</em>&lt;br&gt;<strong>Min Kyung HYUN</strong>, National Evidence-based Healthcare Collaborating Agency, Korea, Rep. of&lt;br&gt;<em>INSULIN PEN VERSUS TRADITIONAL SYRINGE AND VIAL IN PATIENTS WITH DIABETES MELLITUS: SYSTEMATIC REVIEW AND META-ANALYSIS</em>&lt;br&gt;<strong>JinSong GENG</strong>, Health Technology Assessment &amp; Research Center, School of Public Health, Fudan University, Evidence-based Medicine Center, Medical School of Nantong University, China People’s Rep. of&lt;br&gt;<em>COMPARATIVE EFFICACY OF DEXLANSOPRAZOLE VERSUS ESOMEPRAZOLE IN TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE: A SYSTEMATIC REVIEW AND INDIRECT COMPARISON OF RANDOMISED CONTROLLED TRIALS</em>&lt;br&gt;<strong>Ming-Shiang WU</strong>, Division of Gastroenterology, Department of Internal Medicine, National University of Taiwan, Taiwan&lt;br&gt;<em>ADHERENCE AND CONTINUATION OF PHARMACOTHERAPY FOR ALZHEIMER’S DISEASE IN TAIWAN</em>&lt;br&gt;<strong>Jung-Chun WANG</strong>, Division of HTA, Center for Drug Evaluation, Taiwan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S9</td>
<td>Cost Effectiveness Analysis 1</td>
<td><em>AN EFFICIENCY STUDY ON SEVERE HYPONATREMIA IN SIADH AND TOLVAPTAN</em>&lt;br&gt;<strong>Oriol De SOLÀ-MORALES</strong>, HITT, IISPV, Spain&lt;br&gt;<em>NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM USING TANDEM MASS SPECTROMETRY: A COST-EFFECTIVENESS STUDY FROM THAILAND</em>&lt;br&gt;<strong>Kittiphong THIBOONBOON</strong>, Health Intervention and Technology Assessment Program (HITAP), Thailand&lt;br&gt;<em>THE COST-EFFECTIVENESS OF CONTRACTING OUT MATERNAL AND CHILD HEALTH CARE TO PRIVATE HEALTH CARE PROVIDERS IN MALAWI</em>&lt;br&gt;<strong>Elvis Mpakati GAMA</strong>, University of Malawi, Malawi&lt;br&gt;<em>COST-EFFECTIVENESS ANALYSIS OF A HOME CARE PROGRAM IN A MEDICAL COOPERATIVE IN BRAZIL</em>&lt;br&gt;<strong>Fernando BISCIONE</strong>, UNIMED BH, Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S10</td>
<td>Cost Effectiveness Analysis 2</td>
<td><em>COST-EFFECTIVENESS, PUBLIC HEALTH IMPLICATIONS, AND BUDGET</em>&lt;br&gt;<strong>GBR101</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IMPACT OF FFR-GUIDED PCI IN PATIENTS WITH MULTIVESSEL DISEASE IN KOREA -- AN ANALYSIS ALONG THE FAME TRIAL

Uwe SIEBERT, Institute for Public Health, Medical Decision Making and HTA, Dept. of Public Health and HTA, UMIT - University for Health Sciences, Medical Informatics, and Technology / Program on Cardiovascular Research, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School / Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Austria

COST-EFFECTIVENESS OF EPLERENONE COMPARED TO PLACEBO IN PATIENTS WITH CHRONIC HEART FAILURE

Zanfina ADEMI, Melbourne EpiCentre, Department of Medicine, University of Melbourne, Australia

DETERMINANTS OF COST-EFFECTIVENESS OF BIOLOGICAL AGENTS FOR RHEUMATOID ARTHRITIS IN GERMANY

Chris GISSEL, Justus Liebig University, Germany

ECONOMIC ISSUES CONCERNING THE USE OF HELIOX IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN INVASIVE MECHANICAL VENTILATION

Ana Paula Cavalcante de OLIVEIRA, International Health and Biostatistics Unit at the Institute of Hygiene and Tropical Medicine, Portugal

Adjusting for Crossover in the Evaluation of Oncology Technologies: A Case Study in Advanced Melanoma

Simon MCNAMARA, Roche Products Limited, United Kingdom

NICE’s Selective Application of Differential Discounting: Ambiguous, Inconsistent and Unjustified

James O’MAHONY, Trinity College Dublin, Ireland

When Zero Price Breakthrough Medicines Are Not Cost Effective – Implications for Innovation, Incentives and Value Based Pricing

Lee MOORE, Roche Products Ltd, United Kingdom

Economic Evaluation of Single-Tooth Replacement: Dental Implant vs. Bridge

Younhee KIM, National Evidence-based healthcare Collaborating Agency (NECA), Korea, Rep. of

Economic Evaluation of the Reuse of Devices Designed for Single Use in Argentina

O. Ulises GARAY, Institute for Clinical Effectiveness and Health Policy, Argentina

Saving Reagents and Technician Time Using MALDI-TOF MS: A Detailed Economical Evaluation

Jean-Blaise WASSERFALLEN, University hospital of Lausanne (CHUV), Switzerland

Economic Analysis of Drug-Eluting Balloons in Femoro-Popliteal Peripheral Artery Disease

Hyun-Sook CHOI, Medtronic Korea, Korea, Rep. of
A SYSTEMATIC REVIEW ON MICROVOLT T-WAVE ALTERNANS

Gaeun KIM, National Evidence-based Collaborating Agency, Korea, Rep. of

REVIEW OF COST-EFFECTIVENESS EVIDENCE IN THE PREVENTION AND EARLY DETECTION OF COLORECTAL CANCER

Jeong KIM, Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, United Kingdom

HOW INVESTMENT IN A HEXAMINOLEVULINATE (HAL) TECHNOLOGY WOULD BE BENEFICIAL TO PATIENTS AND HEALTHCARE SYSTEMS IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) IN ITALY

Sylvie GABRIEL, Ipsen Pharma SAS, France

ANTENATAL SCREENING OF INFECTIOUS DISEASES: EFFECTIVENESS AND COSTS IN FINLAND

Marjukka MÄ KELÄ, National Institute for Health and Welfare, Finland

ASSESSMENT OF THE QUALITY OF CLINICAL EVIDENCE IN MAJOR SUBMISSIONS TO THE PBAC; HAS IT IMPROVED OVER TIME?

Michael WONDER, Wonder Drug Consulting, Australia

SEVEN MONTHS TO COMPLETE SEVENTY COST-EFFECTIVENESS ANALYSES! HOW TO ACHIEVE THE IMPOSSIBLE USING ADMINISTRATIVE DATA

Sarah BERMINGHAM, University of Toronto, Canada

IMPROVING THE ACCURACY AND COMPARABILITY OF MODEL-BASED ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES FOR REIMBURSEMENT DECISIONS: A METHODOLOGICAL FRAMEWORK FOR THE DEVELOPMENT OF REFERENCE MODELS

Hossein AFZALI, The University of Adelaide, Australia

A SYSTEMATIC REVIEW OF THE CLINICAL EFFECTIVENESS OF PERCUTANEOUS VERTEBROPLASTY AND PERCUTANEOUS BALLOON KYPHOPLASTY FOR THE TREATMENT OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES

Tim GOMERSALL, University of Sheffield, United Kingdom

ECONOMIC EVALUATION OF SCREENING PROGRAMS FOR COLORECTAL CANCER IN ITALY

Matteo RUGGERI, università cattolica del sacro cuore, Italy

MODELLING THE COST-EFFECTIVENESS OF USING DIFFERENT MRI TECHNIQUES TO LOCALISE PROSTATE ABNORMALITIES FOR BIOPSY IN PATIENTS WITH A PREVIOUS NEGATIVE BIOPSY – THE CHALLENGE OF IDENTIFYING THE OPTIMAL STRATEGY

Emma TASSIE, Health Economics Research Unit, University of Aberdeen, Ireland

INPATIENT HOSPITAL COSTS ASSOCIATED WITH OSTEOPOROSIS-RELATED FRACTURES IN CHINA

Russel BURGE, Eli Lilly and Company, United States of America

EVIDENCE GENERATION FOR HTA – PARTNERSHIPS BETWEEN RESEARCH ENTITIES AND DECISION-MAKERS: A NEW ZEALAND CASE STUDY

S14 (18:00-19:00)  HTA Quality and Timeliness  GBR105

S15 (18:00-19:00)  Cost Effectiveness Analysis 3  203A

S16 (18:00-19:00)  Evidence for HTA  203B
David GRAHAM, National Health Committee, Ministry of Health, New Zealand
REPOSITORY OF HEALTHCARE DATABASES IN THAILAND AND JAPAN: POTENTIAL SOURCES FOR HEALTH TECHNOLOGY ASSESSMENT RESEARCH

Surasak SAOKAEW, School of Pharmaceutical Sciences, University of Phayao / The Canon Institute for Global Studies / Graduate School of Public Policy, University of Tokyo, Thailand
THE EXPERIENCE OF AIFA ANTIDIABETIC MONITORING REGISTRY: A TOOL TO ASSESS REAL WORLD DATA FROM AN HTA PERSPECTIVE.

Simona MONTILLA, Italian Medicines Agency, Italy
THE SCIENCE OF JOINT REGISTRIES, HOW THEY CAN BE USED FOR HTA AND TO IMPROVE INDIVIDUAL HEALTH

Janet WALE, Consumer representative, NJRR Consultative Committee, Australia

**S17** (18:00-19:00) HTA Case Studies 2
FINANCIAL VALUE OF QUALITY USE OF MEDICAL TEST - A NATIONAL PROGRAM OF ACUTE LOW BACK PAIN MANAGEMENT
Yeqin ZUO, NPS MedicineWise, Australia

SHOULD HAND TRANSPLANTATION BE REIMBURSED BY A PUBLIC PAYER? AN UP-TO-DATE CASE OF A SWISS HTA FOR DECISION MAKING IN HEALTH CARE

Urs BRÜGGER, Zurich University of Applied Sciences, Switzerland
HTA EVIDENCE OF FENO AND ITS INCLUSION IN SHANGHAI URBAN EMPLOYEE MEDICAL INSURANCE SCHEME IN CHINA

Wenbin LIU, Health Technology Assessment & Research Center, Fudan University / Department of health management and social medicine, School of Public health, Fujian Medical University, China People's Rep. of
DRUG ELUTING BALLOON (DEB) FOR CORONARY HEART DISEASE

Izzuna Mudla Mohamed GHAZALI, Malaysian Health Technology Assessment Section (MaHTAS), Ministry of Health Malaysia, Malaysia

**S18** (18:00-19:00) Evidence and decision making
SYSTEMATIC REVIEW FOR THE WORLD HEALTH ORGANISATION ON NEEDS FOR MEDICAL DEVICES IN OLDER PEOPLE
Wendy BABIDGE, Australia

INDEPENDENTLY OF THE SCIENTIFIC EVIDENCE, WHY CERTAIN HTA RECOMMENDATIONS ARE NOT IMPLEMENTED?

Thomas G. PODER, Canada
THE COST-EFFECTIVENESS OF THE 5X1 DAFNE RCT FOR TYPE 1 DIABETES MELLITUS USING THE SHEFFIELD TYPE 1 DIABETES POLICY MODEL

Hasan BASARIR, United Kingdom
SAFETY INFORMATION GENERATION USING SIGNAL DETECTION METHOD AND CONSEQUENT REGULATORY ACTION

So-Hyeon AHN, Korea, Rep. of

**Tuesday, 18 June**

**S19** (14:00-15:00) Improving Market Access Dossiers for Better Decisions
HOW TO IMPROVE A DRUG MANUFACTURER'S DOSSIER ACCORDING TO AN HTA APPROACH
Angelica CARLETTO, HTA Unit- University Hospital A. Gemelli, Italy
RELATIVE BENEFIT RISK ASSESSMENT DURING CLINICAL DRUG DEVELOPMENT TO EVALUATE MEDICAL VALUE

Manu SONDHI, Sanofi, United States of America
RELATIVE BENEFIT RISK ASSESSMENT DURING CLINICAL DRUG DEVELOPMENT TO EVALUATE MEDICAL VALUE

Norbert WILK, Arcana Institute, Poland

S20 (14:00-15:00) From Evidence to Decision-Making

SYSADOAS. ANALYSIS OF THE INTERNATIONAL CPGS. SAME EVIDENCE, DIFFERENT RECOMMENDATIONS.
Iñaki GUTIÉRREZ IBARLUZEA, OSTeba (Basque Office for Health Technology Assessment), Basque Government, Spain
DEVELOPING THE ONTARIO DECISION FRAMEWORK (ODF): BASING DECISIONS ON CLINICAL EVIDENCE, OPPORTUNITY COST, AND SOCIAL VALUES

Murray KRAHN, University of Toronto, Canada
HTA AND DECISION MAKING: THE EXPERIENCE OF THE ITALIAN HEALTH POLICY FORUM

Americo CICCHETTI, Chairman Health Policy Forum SIHTA, Italy
HEALTH TECHNOLOGY ASSESSMENT AND EFFICIENT HEALTH CARE DECISION MAKING BY THE JUDICIARY SYSTEM IN BRAZIL: THE NATS-UFMG EXPERIENCE

Augusto Cesar SOARES DOS SANTOS JUNIOR, Health Technology Assessment Center (NATS/HC UFMG), Unimed-BH, Brazil

S21 (14:00-15:00) Patient Access Arrangements

OPTIMISING PATIENT ACCESS SCHEMES IN ASIAN SELF-PAY MARKETS
Henry DUMMETT, Double Helix Consulting, India
EXPLORING COMMERCIALLY VIABLE ACCESS SOLUTIONS FOR INNOVATIVE ONCOLOGY DRUGS IN ASIA

Sahil KIRPEKAR, Double Helix Consulting, Singapore
COMMERCIAL-IN-CONFIDENCE: DRUG APPROVALS CONTINGENT ON PRICE-REDUCTIONS OR RISK-SHARING ARRANGEMENTS IN AUSTRALIA AND NEW ZEALAND, AND WHAT DOES THIS MEAN FOR INTERNATIONAL REFERENCE PRICING?

Virginia PRIEST, Double Helix Consulting (Asia Pacific), New Zealand
PRE-COVERAGE ASSESSMENT AND APPRAISAL OF NEW HOSPITAL INTERVENTIONS IN AUSTRIA

Marisa WARMUTH, Ludwig Boltzmann Institute for Health Technology Assessment, Austria

S22 (14:00-15:00) Decision-Making in the Real World

A METHOD TO AID EVIDENCE BASED DECISION MAKING (EBDM) BY IMPROVING TIMELINESS OF DECISIONS AND RESEARCH RESULTS.
Luciana BALLINI, Agenzia Sanitaria e Sociale Regionale Emilia-Romagna, Italy
HTA VS. POPULAR OPINION – WHEN EVIDENCE ISN’T ENOUGH

Anita FITZGERALD, Auckland District Health Board, New Zealand
INTEGRATING EVIDENCE INTO DECISION MAKING IN A HEALTH SERVICE

Richard King, Medical Director – Medicine Program, Southern Health, Technology/Clinical Practice Committee, Southern Health
## Maintaining Stakeholder Involvement in Rapid HTA Processes: The Scottish Approach to Engaging with Industry

**Karen MacPherson**, Healthcare Improvement Scotland, United Kingdom

**Session S23**

### Medical Devices

**DO MSAC’S HEALTH TECHNOLOGY ASSESSMENTS REFLECT THE AUSTRALIAN HEALTH CONTEXT?**

**Anna Stoklosa**, NHMRC Clinical Trials Centre, The University of Sydney, Australia

**NON-MEDICINE RAPID HTAS INFORMING HEALTHCARE DECISION MAKING**

**Susan Myles**, Healthcare Improvement Scotland, United Kingdom

**MEDICAL DEVICE REGISTRIES IN EUROPE: CURRENT STATUS**

**Peter L. Kolominsky-Rabas**, University of Erlangen-Nuremberg, National Cluster of Excellence 'Medical Technologies - Medical Valley EMN', Germany

**INTERVENTIONAL DEVICE-RELATED INCIDENTS: FACTORS THAT INFLUENCE THEIR OCCURRENCE, RECOGNITION AND REPORTING AND A TAXONOMY OF MITIGATION AND PREVENTION STRATEGIES**

**Julie Polisena**, University of Ottawa; Canadian Agency for Drugs and Technologies in Health, Canada

### Hospital based HTA 1

**SEARCH OF EXCELLENCE: APPLICATION OF EFQM TO HOSPITAL BASED HEALTH TECHNOLOGY ASSESSMENT**

**Magda Rosenmoller**, IESE Business School, Germany

**HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT SURVEY: THE EXPANSION OF HTA APPROACHES WITHIN ITALIAN HEALTH CARE ORGANIZATIONS**

**Marco Marchetti**, Health Technology Assessment Unit, “A. Gemelli” University Hospital, Italy

**HOSPITAL-BASED HEALTH TECHNOLOGY: THE EXPERIENCE OF THE CENTERS FOR HEALTH TECHNOLOGY ASSESSMENT (NATS) AT REFERENCE HOSPITALS AND FEDERAL INSTITUTES IN BRAZIL**

**Claudia Pereira**, Oswaldo Cruz Foundation - Fiocruz/ENSP, Brazil

### HTA in hospitals

**HTA EVALUATION OF ENDOSCOPIC RADIOFREQUENCY ABLATION (RFA) FOR TREATMENT OF BARRETT ESOPHAGUS**

**Emanuele Meroni**, Division of Diagnostic Endoscopy and Endoscopic Surgery Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

**RAPID RESPONSE PROCEDURE FOR URGENT MEDICAL DEVICE (MD) USE ON SINGLE PATIENT.**

**Carmen Furno**, HTA Unit - “A. Gemelli” University Hospital, Italy

**EVALUATION SYSTEM FOR THE INVESTIGATIONAL MEDICAL CARE IN JAPAN**

**Kiyoshi Okada**, Pharmaceuticals and Medical Devices Agency, Japan

**THE ROLE OF CLINICAL ONCOLOGY PHARMACIST IN KOREA**

**Jung Tae Kim**, Division of Pharmacy, Kyung Hee University Hospital at Gangdong, Korea, rep of

### National HTA systems

**EVALUATION SYSTEM FOR THE INVESTIGATIONAL MEDICAL CARE IN JAPAN**

**Kiyoshi Okada**, Pharmaceuticals and Medical Devices Agency, Japan

**THE ROLE OF CLINICAL ONCOLOGY PHARMACIST IN KOREA**

**Jung Tae Kim**, Division of Pharmacy, Kyung Hee University Hospital at Gangdong, Korea, rep of
THE ESTABLISHMENT OF A NATIONAL HEALTH TECHNOLOGY ASSESSMENT CENTER IN TAIWAN
Chung-Liang SHIH, Bureau of Planning, Department of Health, The Executive Yuan, Taiwan

A PROPOSED FRAMEWORK FOR INTEGRATION OF HEALTH TECHNOLOGY ASSESSMENT IN POLICY IN INDIA
Mrityunjai KUMAR, Public Health Foundation of India, South Asia Network for Chronic Disease, India

IDENTIFYING AND ASSESSING NEW PROCEDURES: AN INTERNATIONAL PERSPECTIVE
Mirella MARLOW, National Institute for Health and Clinical Excellence, United Kingdom

MODELS FOR CITIZEN AND PATIENT INVOLVEMENT IN HEALTHCARE POLICY: FEASIBILITY AND ACCEPTABILITY TO BELGIAN STAKEHOLDERS
IRINA CLEEMPUT, Belgian Health Care Knowledge Centre (KCE), Belgium

EXAMPLES OF DISCRETE CHOICE EXPERIMENTS FOR MEASURING PATIENTS’ AND PROFESSIONALS’ PREFERENCES: KIDNEY TRANSPLANT ALLOCATION, TESTING FOR SUSPECTED DEEP VEIN THROMBOSIS & SURVEILLANCE FOLLOWING ABDOMINAL AORTIC ANEURYSM SCREENING
Ala SZCZEPURA, University Hospitals Coventry & Warwickshire NHS Trust, United Kingdom

ASSESSING THE IMPACT OF USERS’ INVOLVEMENT IN THE EVALUATION OF ALTERNATIVE MEASURES TO RESTRAINT AND SECLUSION
Marie-Pierre GAGNON, BIOEF - Fundacion vasca de innovacion e investigacion sanitarias, Spain

USING SIMULATION TO INVESTIGATE THE INTEGRATION OF THE ART OF PATIENT EVIDENCE INTO THE SCIENCE OF HTA APPRAISALS
Durhane WONG-RIEGER, Institute for Optimizing Health Outcomes, Canada

USEFULNESS OF HTA: AN ITALIAN MODEL APPLIED TO THE SOUTH AFRICAN CONTEXT
Debjani MUELLER, National Institute of Health and Care Excellence, India

A SURVEY OF HEALTH TECHNOLOGY ASSESSMENT (HTA) ENVIRONMENT IN ASIA
Candice SUN, VitalStrategic Research Institute, China People’s Rep. of

ATTITUDES OF PRIMARY PHYSICIANS FOR CLINICAL PRACTICE GUIDELINE
Jin Yong LEE, College of Medicine, Konyang University, Korea, Rep. of

PUBLIC'S WILLINGNESS TO PAY FOR BRANDED AND GENERIC MEDICINES FOR ACUTE AND CHRONIC DISEASES
Gin Nie Chua, Discipline of Social & Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia

ASIAN STUDY ON VALUE FOR A QALY: KOREAN RESULTS
Jeonghoon Ahn, NECA, Korea, Rep. of
ASSESSING A VALUE OF A QALY IN THAILAND
Sumalai Sompitak, Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand, Thailand

EXPLORING THE FEASIBILITY OF THE INSTRUMENT USED IN DETERMINATION OF WILLINGNESS-TO-PAY PER QUALITY-ADJUSTED LIFE-YEAR IN MALAYSIA
Asrul Akmal Shafie, Universiti Sains Malaysia, Malaysia

DISEASE AND VALUES IN HEALTH TECHNOLOGY ASSESSMENT
Bjorn Hofmann, University of Oslo / University College of Gjøvik / Norwegian Knowledge Centre for the Health Services, Norway

DATA PROTECTION IN HTA: WHY eHEALTH IS MORE THAN AN ISSUE FOR ASSESSMENT
Juergen Hohmann, CEM-IGSS Cellule d'expertise médicale, Luxembourg

AN HABERMASIAN CONTRIBUTION TO IMPROVEMENT OF ETHICS ANALYSIS IN HEALTH TECHNOLOGY ASSESSMENT (HTA).
Bernard Keating, Université Laval, Faculté de théologie et de sciences religieuses, Canada

WHAT CONCEPT OF HEALTH FOR HEALTH TECHNOLOGY ASSESSMENT?
Ken Bond, Institute of Health Economics, Canada

SHORTCOMINGS OF EQ-5D IN A VALUE BASED PRICING FRAMEWORK
David Tordrup, London School of Economics, United Kingdom

UTILITY AND WILLINGNESS TO PAY FOR LUNG CANCER TREATMENTS: PATIENT VERSUS GENERAL POPULATION VALUES IN THAILAND
Sirinthip Petcharapiruch, Outcomes Research, Medical Department, Pfizer (Thailand) Limited, Thailand

STAFF RETENTION AFTER THE PRIVATIZATION OF TOWNSHIP-VILLAGE HEALTH CENTERS: A CASE STUDY FROM THE HAIMEN CITY OF EAST CHINA
Jiayan Huang, Fudan University, China

CRITICAL AND COMPARATIVE STUDY OF THE DOCUMENT OF DECLARATION OF CONFLICT OF INTEREST OF THE BRAZILIAN MINISTRY OF HEALTH
Roberta Wichmann, Brazilian Ministry of Health, Brazil

THE SCIENTIFIC-KNOWLEDGE BASED INSTITUTIONALIZATION OF HEALTH TECHNOLOGY ASSESSMENT: A BIBLIOMETRIC AND NETWORK ANALYSIS
Philippe Gorry, Research Unit in Theoretical and Applied Economics, UMR CNRS 5113, University of Montesquieu Bordeaux IV, France

WHAT’S IN A NAME? - MAPPING THE DIFFERENT HTA PRODUCTS OF INAHTA MEMBERS.
Tracy Merlin, Adelaide Health Technology Assessment (AHTA), Discipline of Public Health, School of Population Health, University of Adelaide, Australia

DEVELOPING TRAINING FOR HTA AGENCY STAFF, THE BOARD AND COMMITTEE MEMBERS ON PATIENT AND PUBLIC INVOLVEMENT – AN ART OR A SCIENCE?
Lizzie Amis, National Institute for Health and Clinical Excellence (NICE),
United Kingdom

TRAINING NEEDS IN POSTGRADUATE HTA EDUCATION
Christopher CARROLL, University of Sheffield, United Kingdom

S33 (17:00-18:00) Coverage and Pricing 203A

OPPORTUNITIES TO RELEASE CONSIDERABLE RESOURCES FROM EXISTING DRUGS – KEY ROLE OF HTA AGENCIES AND PAYERS
Brian GODMAN, Brystol-Myers Squibb Australia, United Kingdom

COMPARISON OF OFF-PATENT PRICING EVOLUTION ACROSS HTA BASED FUNDING SYSTEMS IN ASIA PACIFIC
Hansoo Kim, Bristol-Myers Squibb, Australia

IMPLICATIONS OF GLOBAL PRICING POLICIES OF PHARMACEUTICALS FOR ACCESS THE INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES
Andres PICHON-RIVIERE, University of Witwatersrand, Argentina

S34 (17:00-18:00) Public health and safety 203B

EXPLORING THE FISCAL IMPACT OF INFORMAL CAREGIVING IN CANADA
Josephine JACOBS, University of Toronto, Canada

USA FUNGAL MENINGITIS OUTBREAK AFTER EPIDURAL STEROID INJECTIONS: QUALITY, EPIDEMIOLOGY AND TECHNOLOGY ASSESSMENT ISSUES
David WONG, Presbyterian St Luke's Medical Center, United States of America

REGIONAL DISPROPORTIONS IN ACCESS TO HEALTHCARE IN POLAND – THE CASE OF OPHTHALMOLOGY
Robert PLISKO, HTA Consulting, Poland

RISK OF SERIOUS INFECTIONS BY ANTI-TNF-α AGENTS IN KOREAN PATIENTS WITH RHEUMATOID ARTHRITIS
Joongyub LEE, Clinical Epidemiology, Medical Research Collaborating Center, Seoul National University Hospital, Korea, Rep. of

S35 (17:00-18:00) Patient and Citizen Involvement 208A

ACCOMMODATION OF DIFFERENT CULTURAL PERSPECTIVES IN PATIENT REPORTED OUTCOMES IN GLOBAL CLINICAL TRIALS
Alaa HAMED, Sanofi, United States of America

PATIENTS’ ACCEPTANCE REGARDING SHARED DECISION MAKING IN THE BRAZILIAN RHEUMATOLOGIC CARE
Raphael BATTISTI, Universidade Federal de Sao Carlos, Brazil

DEVELOPING A MODEL OF PUBLIC INVOLVEMENT FOR THE NICE PATIENT EXPERIENCES GUIDELINE AND QUALITY STANDARD
Sophie STANISZEWSKA, Royal College of Nursing Research Institute, University of Warwick, United Kingdom

INCLUDING STAKEHOLDER VOICES IN DELIBERATIVE METHODS (MINI-PUBLICS) FOR HTA DECISION-MAKING. AN ART OR A SCIENCE?
Jackie M STREET, School of Population Health, University of Adelaide, Australia